In Achondroplasia OMIM 100800 (FGFR3, OMIM 100800), the master switch sits on the ↓ DOWN branch ([F] forced below); the healthy state is the OFF well. The forced corrective direction is to lower s toward OFF branch (polarity: clear). Classification: ✓ Recovers an existing standard. Direction only — no dose, no efficacy magnitude.
The disease maps to an R19 double-well whose corrective lever is read straight off the cusp (barrier 0.6556, γ 1.6194, spinodal 0.7932). The corrective direction is forced [F]; the agent names below are direction-concordant labels at grade [O] (no dose, no efficacy or safety magnitude). This is a research hypothesis offered to experts, not medical advice.
The emergence switch
The switch for Achondroplasia OMIM 100800 is an R19 double-well emerged from the real proximal-promoter DNA of FGFR3. Its geometry is fixed by measured stiffness γ (never fitted); the numbers below are read directly off that cusp.
emergent axis
↓ DOWN [F]
healthy branch
OFF
lesion
GOF
γ (stiffness)
1.6194
barrier
0.6556
spinodal
0.7932
s_on / s_off
1.2726 / -1.2726
fragility
0.00
corrective polarity
clear
forced direction
lower s toward OFF branch
Chemistry feasibility (DIRECTION only [O]). small-molecule recrossing of the fold is geometrically harder (barrier 0.6556 at neutral drive; lower barrier = smaller drive to supply). [O] -- no affinity/potency/dose/efficacy asserted.
The derived corrective lever
The cusp forces a corrective direction: lower s toward OFF branch. This is the load-bearing output of the framework — it is [F] forced, and it is falsifiable. 2 lever families are derived; the lead is h-restore (drive modulator).
Mechanism. remove / oppose the drive (clear the accumulating load that pins the disease branch)
Applies to. allele-agnostic (downstream/environmental tilt)
favoured when the switch is fragile -- a small drive shift recrosses the fold
Falsifier. If clearing/opposing the accumulating NPR2 does NOT relieve the disease branch in a FGFR3 model, the h-restore(clear) lever is refuted for this axis.
EXCLUDED: gain-of-function -- the lesion is not a destabilised healthy product to stiffen; the corrective move is to clear/oppose the toxic drive (h-restore)
Falsifier. If a folding-stabiliser/chaperone does NOT re-deepen the healthy well for a residual FGFR3 allele (no rescue that a null allele lacks), the gamma-restore lever is refuted; null alleles are excluded by construction.
Agents mapped onto the lever
✓ Agreement with established practice. The corrective direction derived here (lower s toward OFF branch) independently matches an agent already in clinical use for this disease: CNP analogue (vosoritide). The geometry recovered known medicine — this is a validation signal for the logic, not a new treatment claim by this kit.
Existing agents whose known action is direction-concordant with the derived lever (status as pinned in the corpus; no dose, no efficacy magnitude).
Legeai-Mallet lineage; infigratinib paediatric program
decrease
clinical
3
◇ in trials
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.
Direction-only candidate leads (corpus join)
Each lead is surfaced only because its known mechanism points the same way as the derived lever, and each comes with a source and a falsifier. None is a treatment.
Mechanism. A CNP analogue that activates natriuretic-peptide receptor B (NPR-B) in the growth plate, whose downstream signalling antagonises the over-active FGFR3 pathway driving the gain-of-function achondroplasia phenotype. Direction: decrease / oppose the FGFR3 over-signalling. Engaged node: NPR-B (the agent acts on the receptor that counter-regulates FGFR3, not on FGFR3 itself). Allele scope: agnostic -- counters the pathway downstream of the lesion. Mapped to achondroplasia (a GOF lesion, for which only the decrease / h-restore direction is admissible). An approved agent; the geometry's clear direction recovers it.
✓ This is a rediscovery. Vosoritide is approved for achondroplasia and opposes FGFR3 over-signalling; the clear/decrease direction recovered the approved agent.
Safety (qualitative; no magnitude). CNP analogue; injection-site-reaction and transient-blood-pressure signals noted on label (qualitative; no magnitude)
Falsifier. If vosoritide (a pathway decrease agent) clearing/opposing the accumulating load does NOT relieve the DOWN [F] disease branch in a FGFR3 model, the h-restore(clear) direction is refuted for vosoritide here.
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.
Evidence & provenance
What is reproduced vs. cited for this page.
element
grade
basis
R19 switch & cusp geometry (this page)
[V] verified
emerged from measured promoter γ of FGFR3; deterministic, 2×sha256 identical
corrective direction
[F] forced
forced by the cusp sign; falsifiable (see lever falsifiers)
mapped agents / leads
[O] open
direction-concordance only; corpus-pinned (2026-06-21); no dose, no efficacy/safety magnitude
Reading the agent column. VALIDATION SIGNAL -- the agent is already approved / established standard for this disease, so the direction logic recovered known clinical practice. Not a new claim by this kit. GENUINE HYPOTHESIS -- no approved indication for this disease; the direction match is a direction-only, untested [O] lead. Basis field grades the evidence (investigational here / in a related condition / off-label / speculative).